<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37291486</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2369</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>BMC nephrology</Title><ISOAbbreviation>BMC Nephrol</ISOAbbreviation></Journal><ArticleTitle>A survival case of visceral disseminated varicella zoster virus infection in a patient with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>164</StartPage><MedlinePgn>164</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">164</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12882-023-03223-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Visceral disseminated varicella zoster virus (VZV) infection is a rare but life-threatening complication in immunosuppressed patients. Herein, we report a survival case of visceral disseminated VZV infection in a patient with systemic lupus erythematosus (SLE).</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 37-year-old woman was diagnosed as SLE and initial induction therapy was started. Two months after starting the immunosuppressive therapy consisting of 40&#xa0;mg of prednisolone (PSL) and 1500&#xa0;mg of mycophenolate mofetil (MMF) daily, she suddenly developed strong abdominal pain, which was required opioid analgesics, followed by systemic skin blisters, which were diagnosed as varicella. Laboratory findings showed rapid exacerbation of severe liver failure, coagulation abnormalities and increased numbers of blood VZV deoxyribonucleic acid (DNA). Therefore, she was diagnosed as visceral disseminated VZV infection. Multidisciplinary treatment with acyclovir, immunoglobulin and antibiotics was started, the dose of PSL was reduced, and MMF was withdrawn. By their treatment, her symptoms were resolved and she finally discharged.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our case highlights the importance of a clinical suspicion of visceral disseminated VZV infections, and the necessity of immediate administration of acyclovir and reduced doses of immunosuppressant to save patients with SLE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ishino</LastName><ForeName>Yuri</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Renal Division, Department of Internal Medicine, Iwata City Hospital, 512-3 Ohkubo, Iwata, Shizuoka, 438-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fukasawa</LastName><ForeName>Hirotaka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Renal Division, Department of Internal Medicine, Iwata City Hospital, 512-3 Ohkubo, Iwata, Shizuoka, 438-8550, Japan. hfukasawaucsd@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitamoto</LastName><ForeName>Shuhei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Renal Division, Department of Internal Medicine, Iwata City Hospital, 512-3 Ohkubo, Iwata, Shizuoka, 438-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakagami</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Renal Division, Department of Internal Medicine, Iwata City Hospital, 512-3 Ohkubo, Iwata, Shizuoka, 438-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaneko</LastName><ForeName>Mai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Renal Division, Department of Internal Medicine, Iwata City Hospital, 512-3 Ohkubo, Iwata, Shizuoka, 438-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasuda</LastName><ForeName>Hideo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furuya</LastName><ForeName>Ryuichi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Renal Division, Department of Internal Medicine, Iwata City Hospital, 512-3 Ohkubo, Iwata, Shizuoka, 438-8550, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Nephrol</MedlineTA><NlmUniqueID>100967793</NlmUniqueID><ISSNLinking>1471-2369</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>X4HES1O11F</RegistryNumber><NameOfSubstance UI="D000212">Acyclovir</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014645" MajorTopicYN="N">Herpesvirus 3, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002644" MajorTopicYN="Y">Chickenpox</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006562" MajorTopicYN="Y">Herpes Zoster</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073618" MajorTopicYN="Y">Varicella Zoster Virus Infection</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000212" MajorTopicYN="N">Acyclovir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal pain</Keyword><Keyword MajorTopicYN="N">Mycophenolate mofetil (MMF)</Keyword><Keyword MajorTopicYN="N">Skin blisters</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus (SLE)</Keyword><Keyword MajorTopicYN="N">Varicella zoster virus</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>9</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>8</Day><Hour>23</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37291486</ArticleId><ArticleId IdType="pmc">PMC10251651</ArticleId><ArticleId IdType="doi">10.1186/s12882-023-03223-0</ArticleId><ArticleId IdType="pii">10.1186/s12882-023-03223-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985;152:1172&#x2013;1181. doi: 10.1093/infdis/152.6.1172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/152.6.1172</ArticleId><ArticleId IdType="pubmed">3905982</ArticleId></ArticleIdList></Reference><Reference><Citation>David DS, Tegtmeier BR, O'Donnell MR, Paz IB, McCarty TM. Visceral varicella-zoster after bone marrow transplantation: report of a case series and review of the literature. Am J Gastroenterol. 1998;93:810&#x2013;813. doi: 10.1111/j.1572-0241.1998.230_a.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.1998.230_a.x</ArticleId><ArticleId IdType="pubmed">9625133</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarty EF, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus. 2013;22:238&#x2013;244. doi: 10.1177/0961203312470186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203312470186</ArticleId><ArticleId IdType="pubmed">23257402</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothwell WS, Gloor JM, Morgenstern BZ, Milliner DS. Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Transplantation. 1999;68:158&#x2013;161. doi: 10.1097/00007890-199907150-00030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007890-199907150-00030</ArticleId><ArticleId IdType="pubmed">10428286</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehr T, Bossart W, Wahl C, Binswanger U. Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature. Transplantation. 2002;73:608&#x2013;611. doi: 10.1097/00007890-200202270-00023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007890-200202270-00023</ArticleId><ArticleId IdType="pubmed">11889440</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauzurica R, Bayes B, Frias C, Fontsere N, Hernandez A, Matas L, et al. Disseminated varicella infection in adult renal allograft recipients: role of mycophenolate mofetil. Transplant Proc. 2003;35:1758&#x2013;1759. doi: 10.1016/S0041-1345(03)00684-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0041-1345(03)00684-5</ArticleId><ArticleId IdType="pubmed">12962784</ArticleId></ArticleIdList></Reference><Reference><Citation>Doki N, Miyawaki S, Tanaka M, Kudo D, Wake A, Oshima K, et al. Visceral varicella zoster virus infection after allogeneic stem cell transplantation. Transpl Infect Dis. 2013;15:314&#x2013;318. doi: 10.1111/tid.12073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tid.12073</ArticleId><ArticleId IdType="pubmed">23551634</ArticleId></ArticleIdList></Reference><Reference><Citation>Habuka M, Wada Y, Kurosawa Y, Yamamoto S, Tani Y, Ohashi R, et al. Fatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with lupus nephritis and rheumatoid arthritis-possible association with mycophenolate mofetil and high-dose glucocorticoid therapy: a case report. BMC Res Notes. 2018;11:165. doi: 10.1186/s13104-018-3271-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-018-3271-3</ArticleId><ArticleId IdType="pmc">PMC5838883</ArticleId><ArticleId IdType="pubmed">29506558</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassia V, Croce A, Ravanini P, Leutner M, Saglietti C, Fangazio S, et al. Unusual presentation of fatal disseminated varicella zoster virus infection in a patient with lupus nephritis: a case report. BMC Infect Dis. 2020;20:538. doi: 10.1186/s12879-020-05254-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05254-6</ArticleId><ArticleId IdType="pmc">PMC7376941</ArticleId><ArticleId IdType="pubmed">32703300</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550&#x2013;2558. doi: 10.1056/NEJMoa051135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa051135</ArticleId><ArticleId IdType="pubmed">16354891</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland P, Wald ER, Mirro JR, Jr, Yunis E, Albo VC, Wollman MR, et al. Progressive varicella presenting with pain and minimal skin involvement in children with acute lymphoblastic leukemia. J Clin Oncol. 1995;13:1697&#x2013;1703. doi: 10.1200/JCO.1995.13.7.1697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.1995.13.7.1697</ArticleId><ArticleId IdType="pubmed">7602360</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa Y, Nakano K, Tokutsu K, Nakayamada S, Matsuda S, Fushimi K, et al. Short-term prognostic factors in hospitalized herpes zoster patients and its associated cerebro-cardiovascular events: a nationwide retrospective cohort in Japan. Front Med (Lausanne) 2022;9:843809. doi: 10.3389/fmed.2022.843809.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.843809</ArticleId><ArticleId IdType="pmc">PMC8931312</ArticleId><ArticleId IdType="pubmed">35308501</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiller GJ, Nimer SD, Gajewski JL, Golde DW. Abdominal presentation of varicella-zoster infection in recipients of allogeneic bone marrow transplantation. Bone Marrow Transplant. 1991;7:489&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">1843181</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi T, Karasuno T, Hasegawa T, Yasumi M, Kawamoto S, Murakami M, et al. Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation: importance of empiric therapy with acyclovir. Bone Marrow Transplant. 2000;25:1003&#x2013;1005. doi: 10.1038/sj.bmt.1702340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bmt.1702340</ArticleId><ArticleId IdType="pubmed">10800071</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Oteyza J, Pascual C, Garcia-Larana J, Odriozola J, Rocamora A, Navarro JL. Abdominal presentation of varicella zoster infection after bone marrow transplantation. Bone Marrow Transplant. 1992;9:217.</Citation><ArticleIdList><ArticleId IdType="pubmed">1511259</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuto Y, Kawamura M, Namikawa A, Takahashi H, Shibuya Y. Successful management of visceral disseminated varicella zoster virus infection during treatment of membranous nephropathy: a case report. BMC Infect Dis. 2019;19:625. doi: 10.1186/s12879-019-4193-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-019-4193-y</ArticleId><ArticleId IdType="pmc">PMC6632194</ArticleId><ArticleId IdType="pubmed">31307420</ArticleId></ArticleIdList></Reference><Reference><Citation>Au WY, Ma SY, Cheng VC, Ooi CG, Lie AK. Disseminated zoster, hyponatraemia, severe abdominal pain and leukaemia relapse: recognition of a new clinical quartet after bone marrow transplantation. Br J Dermatol. 2003;149:862&#x2013;865. doi: 10.1046/j.1365-2133.2003.05656.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2133.2003.05656.x</ArticleId><ArticleId IdType="pubmed">14616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyland JM, Butterworth J. Severe acute visceral pain from varicella zoster virus. Anesth Analg. 2003;97:1117&#x2013;1118. doi: 10.1213/01.ANE.0000081789.58565.31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ANE.0000081789.58565.31</ArticleId><ArticleId IdType="pubmed">14500167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797&#x2013;808. doi: 10.1002/acr.21664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21664</ArticleId><ArticleId IdType="pmc">PMC3437757</ArticleId><ArticleId IdType="pubmed">22556106</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79:713&#x2013;723. doi: 10.1136/annrheumdis-2020-216924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100:S1&#x2013;S276. doi: 10.1016/j.kint.2021.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.021</ArticleId><ArticleId IdType="pubmed">34556256</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343:1156&#x2013;62. doi: 10.1056/NEJM200010193431604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200010193431604</ArticleId><ArticleId IdType="pubmed">11036121</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford) 2010;49:128&#x2013;140. doi: 10.1093/rheumatology/kep346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep346</ArticleId><ArticleId IdType="pmc">PMC2789586</ArticleId><ArticleId IdType="pubmed">19933596</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan A, Rayes HA, Lazova T, Anderson N, Bonilla D, Su J, et al. Herpes zoster in SLE: prevalence, incidence and risk factors. Lupus Sci Med. 2022;9:e000574. doi: 10.1136/lupus-2021-000574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000574</ArticleId><ArticleId IdType="pmc">PMC8753438</ArticleId><ArticleId IdType="pubmed">35017186</ArticleId></ArticleIdList></Reference><Reference><Citation>Rondaan C, de Haan A, Horst G, Hempel JC, van Leer C, Bos NA, et al. Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases. Arthritis Rheumatol. 2014;66:3122&#x2013;3128. doi: 10.1002/art.38804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38804</ArticleId><ArticleId IdType="pubmed">25223407</ArticleId></ArticleIdList></Reference><Reference><Citation>Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014;5:626. doi: 10.3389/fimmu.2014.00626.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00626</ArticleId><ArticleId IdType="pmc">PMC4259107</ArticleId><ArticleId IdType="pubmed">25538710</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J Autoimmun. 2015;57:24&#x2013;29. doi: 10.1016/j.jaut.2014.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2014.11.004</ArticleId><ArticleId IdType="pubmed">25586449</ArticleId></ArticleIdList></Reference><Reference><Citation>Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J Allergy Clin Immunol. 2022;149:1525&#x2013;1560. doi: 10.1016/j.jaci.2022.01.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.01.025</ArticleId><ArticleId IdType="pubmed">35176351</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>